Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A vaccine component consisting of *Streptococcus pneumoniae* serotype 6A capsular polysaccharide chemically conjugated to the carrier protein CRM197 (a non-toxic mutant of diphtheria toxin). This conjugate antigen is included in several pneumococcal conjugate vaccines (PCVs) including PCV15, PCV20, and PCV21. The conjugation to CRM197 enhances immunogenicity by converting the T-independent polysaccharide antigen into a T-dependent antigen, making it more effective in young children. This specific serotype (6A) is structurally similar to serotype 6B but with one difference in the rhamnose-ribitol linkage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pneumococcal 6A-CRM197 conjugate.